On April 6, Governor John Hickenlooper signed SB 71 into law.

Read the ASBM letter to Senator Cadman here.

• Bill Information

  The bill allows a pharmacist to substitute a biological product if FDA has determined that the biological product is interchangeable with the prescribed biological product and if the practitioner has not indicated that the prescription must be dispensed as written. Within a reasonable time after a pharmacist dispenses a biological product, the dispensing pharmacist or the pharmacist’s designee must communicate to the prescribing practitioner the specific biological product dispensed to the patient, including the name of the product and manufacturer, through an electronic system.

• Archive

  State Lawmakers Weigh Issue Of ‘Biosimilars’ — New, Life-Saving Drugs

  March 26, 2015

  DENVER (CBS4) – Much cheaper, life-saving drugs could become available this year. They are called biosimilars and are copycat versions of drugs for diseases like rheumatoid arthritis, breast cancer and psoriasis. A bill before Colorado lawmakers would let pharmacists substitute the biosimilars for brand name drugs. The medications are different from the generics that have […]

  Biosimilars bill approved by Colorado Legislature

  March 26, 2015

  Colorado’s biosimilars bill letting pharmacists provide patients with generic drugs in place of name-brand biotech medicines now needs only a governor’s signature to become law. The state House of Representatives passed the bill with only one ‘no’ vote on Tuesday, and it heads on to John Hickenlooper desk.   Read more here.

  Biosimilars bill approved by Colorado Legislature

  March 26, 2015

  Colorado’s biosimilars bill letting pharmacists provide patients with generic drugs in place of name-brand biotech medicines now needs only a governor’s signature to become law. The state House of Representatives passed the bill with only one ‘no’ vote on Tuesday, and it heads on to John Hickenlooper desk.   Read more here.

  Biosimilars Forum in Colorado

  December 21, 2012

  On December 6th, Chairman Richard Dolinar, M.D., and Executive Director Michael Reilly toured a biologic manufacturing facility in Longmont, CO. Several ASBM members also participated on the tour which was arranged to help attendees better understand the complexities of manufacturing biologics.

  Biosimilars Forum in Colorado

  December 21, 2012

  On December 6th, Chairman Richard Dolinar, M.D., and Executive Director Michael Reilly toured a biologic manufacturing facility in Longmont, CO. Several ASBM members also participated on the tour which was arranged to help attendees better understand the complexities of manufacturing biologics.

  Rocky Mountain Life Science Investor & Partnering Conference

  June 17, 2011

  September 21-23, 2011 Denver, Colorado Read More

  Bioscience Discovery Evaluation Grant Program (BDEGP)

  June 17, 2011

  The Bioscience Discovery Evaluation Grant Program (BDEGP) was created in 2006 by the Colorado General Assembly to grow the bioscience industry in the state. The goal was to stimulate jobs and create new bioscience companies based on promising discoveries made at the state’s major research institutions. Read More

  Colorado Bioscience Roadmap 2008 – Colorado Bioscience Association


  June 17, 2011

  Roadmap 2008 Battelle Report for the Colorado BioScience Association. Read More

  Bioscience Colorado Industry Cluster Profile 2010

  June 17, 2011

  The Metro Denver Economic Development Corporation. Read More

  Bioscience in Colorado Fact Sheet

  June 17, 2011

  The Colorado Bioscience Association has published this fact sheet that includes information on the biotechnology industry in Colorado and comparative rankings with the national biotechnology industry in the United States. Read More